Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05986084 · ClinicalTrials.gov registry record · Phase 4
Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana
A Phase 4 study of Breast Feeding and Pre-Exposure Prophylaxis (PrEP), sponsored by Beth Israel Deaconess Medical Center.
- Active
- Registry status
- Phase 4
- Development phase
- 500
- Enrollment target
- 2
- Study locations
NCT05986084 is a Phase 4 study of Breast Feeding and Pre-Exposure Prophylaxis (PrEP) that is active but no longer recruiting, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 500 participants, above the 127-participant average among 7 other Breast Feeding trials with a reported enrollment target (294% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT05986084, a Phase 4 study of Breast Feeding and Pre-Exposure Prophylaxis (PrEP), is active but no longer recruiting, sponsored by Beth Israel Deaconess Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 500 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this this hybrid safety/implementation study is to evaluate whether using long-acting cabotegravir (CAB-LA) for HIV prevention (PrEP) is acceptable, feasible and safe in post-partum people who are breastfeeding. The main question\[s\] it aims to answer are: * Will CAB-LA injections work well as a way to prevent HIV infection in post-partum people? * Will CAB-LA injections be safe in post-partum people and their infants who will be breastfeeding? Participants without HIV who are admitted to the maternity ward after having delivered a baby will be offered to start CAB-LA PrEP. Those who choose to participate will receive their first dose (injection) at the maternity ward and their follow up doses (injections) at their local clinic when they come for routine post-partum and pediatric care. Participants and their infants will be followed in the study for 24 months. We will be following how many people come on-time for their CAB-LA injections, how often they keep coming back, and the reasons they continue (or stop) these injections. We will also test people for HIV at all of their visits to see how many people get HIV during the study. We will also measure the levels of the medication in the blood of the post-partum people and their infants (who may be getting some of the CAB-LA in breastmilk) and evaluate to see if their is any impact of CAB-LA on the health of the post-partum person or their infants.
Conditions Studied
Interventions
- DRUG Cabotegravir Injection [Apretude]
Study Locations (2)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Other
- Botswana Harvard AIDS Institute Partnership - Gaborone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-11-30 |
| Est. Completion | 2027-11-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05986084
The ClinicalTrials.gov registry entry for NCT05986084 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 127-participant average among 7 other Breast Feeding trials with a reported enrollment target (294% higher). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Feeding appearing as the primary indexed condition, and to 1 intervention - of which Cabotegravir Injection [Apretude] is the first listed.
NCT05986084 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Other.
Frequently Asked Questions
What is clinical trial NCT05986084 about?
NCT05986084 is a clinical study titled "Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana". The goal of this this hybrid safety/implementation study is to evaluate whether using long-acting cabotegravir (CAB-LA) for HIV prevention (PrEP) is acceptable, feasible and safe in post-partum people who are breastfeeding. The main question\[s\] it aims to answer are: * Will CAB-LA injections work...
What is the current status of trial NCT05986084?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 500 participants. The study started on 2023-11-30. Estimated completion is 2027-11-30.
What conditions does trial NCT05986084 study?
This clinical trial studies the following conditions: Breast Feeding, Pre-Exposure Prophylaxis (PrEP).
What interventions are being tested in trial NCT05986084?
The interventions under investigation include: Cabotegravir Injection [Apretude] (DRUG).
Who is sponsoring clinical trial NCT05986084?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05986084 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Feeding
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Starting Early to Prevent Obesity Using Telehealth (StEP OUT): Intervention Development Trial
RECRUITING · NA
-
Mayo Clinic Health System Northwest Wisconsin Integrated Maternal Postpartum Appointment Combination
RECRUITING · NA
-
Developmental Impacts of Microplastics Exposure in Early Life
RECRUITING
-
At-the-Breast vs. Expressed Human Milk: Genesis of Infant Nutrition (BEGIN)
RECRUITING
-
South Carolina WIC Telehealth Solution
COMPLETED · NA
-
Meditation for NICU Moms
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.